1. Generics Bulletin
  2. >>Legal & IP

Medicines Patent Pool Expands From HIV To Hepatitis C & TB, With 100 Projects On The Go

 
• By Ian Schofield

Drugs for hepatitis C and tuberculosis are now being licensed for generic production under the aegis of the Medicines Patent Pool, which says it now has 15 generic manufacturing partners working on more than 100 projects across the hepatitis C, TB and HIV areas.

Developing image
The Medicines Patent Pool has expanded its licensing of drugs for poorer countries

The Medicines Patent Pool, which helps negotiate voluntary licenses for the manufacture of generic versions of patented drugs for use in low- and middle-income countries, has expanded its reach beyond HIV medications to include hepatitis C and tuberculosis, and says it is “confident that we can play a role in international efforts to meet treatment goals in coming years.”

As of December 2016, the MPP’s 15 generic manufacturing partners were working on more than 100 projects to develop active...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

 
• By Dean Rudge

Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.

Patent Settlements Are ‘Critically Necessary’ As AAM Calculates $423bn Savings Since 2013

 
• By Urtė Fultinavičiūtė

The US healthcare system saved billions by allowing early market entry for generic and biosimilar medicines through patent settlements. However, long-winded litigations with an expensive price tag and the Senate’s reintroduced pay-for-delay bill are set to make the situation even more dire.

AstraZeneca Agrees Last-Minute $50m Settlement In Seroquel XR Delay Case

 
• By Dean Rudge

A class action suit alleging AstraZeneca delayed generic competition for Seroquel XR by making illegal agreements that stifled market entry for generic quetiapine competitors has been dismissed after the originator agreed to settle for tens of millions of dollars.

Trump’s FTC Continues The Mission Of Eliminating Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, president Donald Trump’s Federal Trade Commission carries the torch in a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon told Generics Bulletin what it means for the generic drug industry.

More from Generics Bulletin

Regulatory Recap: EU Pharma Package Progresses Forward With Extended Data Protection

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By Dean Rudge

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.